Overview

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Status:
Recruiting

Trial end date:
2021-05-30

Target enrollment:

Participant gender:

Summary

This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node negative, HER-2 positive and small tumor size breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Capecitabine
Trastuzumab
Vinorelbine